Folketrygdfondet bought a new position in Oculis Holding AG (NASDAQ:OCS – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor bought 182,800 shares of the company’s stock, valued at approximately $3,651,000. Oculis makes up 0.2% of Folketrygdfondet’s holdings, making the stock its 10th largest position.
Several other large investors have also made changes to their positions in OCS. China Universal Asset Management Co. Ltd. increased its holdings in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC acquired a new stake in Oculis in the 4th quarter valued at $80,000. Marshall Wace LLP acquired a new stake in Oculis in the 2nd quarter valued at $393,000. Geode Capital Management LLC increased its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.
Oculis Stock Up 0.3%
Shares of Oculis stock opened at $11.00 on Friday. The business has a 50-day moving average of $25.30 and a 200-day moving average of $24.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The company has a market capitalization of $637.78 million, a PE ratio of -5.16 and a beta of 0.23. Oculis Holding AG has a 1-year low of $10.52 and a 1-year high of $34.47.
Analysts Set New Price Targets
Several brokerages recently issued reports on OCS. JPMorgan Chase & Co. lowered their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Stifel Nicolaus lowered their price target on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st. Robert W. Baird lowered their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Guggenheim lowered their price target on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.33.
Read Our Latest Analysis on OCS
Oculis Profile
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Oculis
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding OCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oculis Holding AG (NASDAQ:OCS – Free Report).
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
